- Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE
- Hofseth Biocare ASA: THIRD QUARTER 2022 FINANCIAL REPORT
- Hofseth Biocare ASA: STANFORD SCHOOL OF MEDICINE SUCCESSFULLY COMPLETES PRE-CLINICAL TRIAL WORK TESTING PROGO® BIOACTIVE PEPTIDES IN EFFECTIVE GUT HEALTH SUPPORT
- Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING
- Hofseth Biocare ASA: HBC’S PROGO BIOACTIVE PEPTIDES NOW IS A “NEW DIETARY INGREDIENT” (NDI) FOR THE US FDA
- Hofseth Biocare ASA: SECOND QUARTER & H1 2022 FINANCIAL REPORT
- Hofseth Biocare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
- Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
- Hofseth Biocare ASA: JON OLAV ØDEGÅRD APPOINTED NEW CEO OF HBC
- Hofseth Biocare ASA: NOTIFIABLE TRANSACTION – REDELIVERY OF SHARES
More ▼
Key statistics
On Thursday, Hofseth Biocare ASA (HBC:OSL) closed at 3.10, 40.27% above the 52 week low of 2.21 set on Dec 15, 2022.
52-week range
Markit short selling activity
Open | 3.00 |
---|---|
High | 3.13 |
Low | 2.96 |
Bid | 3.02 |
Offer | 3.09 |
Previous close | 3.09 |
Average volume | 61.07k |
---|---|
Shares outstanding | 395.08m |
Free float | 224.79m |
P/E (TTM) | -- |
Market cap | 1.22bn NOK |
EPS (TTM) | -0.3733 NOK |
Data delayed at least 15 minutes, as of Jan 26 2023.
More ▼